Treatment of focal segmental glomerulosclerosis

Patrizia Passerini, Claudio Ponticelli

Research output: Contribution to journalArticlepeer-review


The prognosis of untreated patients with focal segmental glomerulosclerosis is poor, as the disease progress to endstage renal disease in approximately 50-70% of nephrotic patients. Although focal segmental glomerulosclerosis was initially considered to be a steroid-resistant disease, several studies have shown a better responsiveness to more prolonged courses of steroids. For patients with steroid-resistant or -dependent focal segmental glomerulosclerosis, cyclosporine A and cytotoxic agents have shown efficacy in clinical trials. Plasmapheresis or LDL-apheresis may represent a rescue treatment in patients who do not respond to other therapies. The role of other agents used in focal segmental glomerulosclerosis, including azathioprine, mycophenolate mofetil, tacrolimus, pefloxacin or vitamin E is still poorly defined.

Original languageEnglish
Pages (from-to)189-193
Number of pages5
JournalCurrent Opinion in Nephrology and Hypertension
Issue number2
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine


Dive into the research topics of 'Treatment of focal segmental glomerulosclerosis'. Together they form a unique fingerprint.

Cite this